DeepCure

📍 Boston, United States🗓 Founded 2018👥 45 employees💰 Last funded Jan 2024
Biotechnology Research🌐 deepcure.com
Website LinkedIn
DeepCure discovers transformative small molecule therapies for immune and inflammatory diseases. The company uses a chemistry platform that combines AI, physics-based tools and automated chemical synthesis to identify truly novel molecules that address unsolved challenges in drug discovery. The pipeline includes an oral STAT6 program with multiple novel scaffolds and an oral BRD4(BD2) program with the first truly selective inhibitor. DeepCure expects to start in clinical trials in 2025.
3
Total investors
1
Early stage
1
Mid stage
1
Late stage
2018
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
Israel
1
Investor activity2018–2024 · investors recorded per year
201812021120241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in DeepCure?
DeepCure has 3 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage and 1 late-stage investors.
When did DeepCure last raise funding?
The most recent investment in DeepCure recorded on gritt.io was in January 2024.
When was DeepCure founded?
DeepCure was founded in 2018.
What industry is DeepCure in?
DeepCure operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is DeepCure based?
DeepCure is headquartered in Boston, United States.